Chung SW - Search Results

1

The novel strategy for concurrent chemoradiotherapy by conjugating the apoptotic cell-binding moiety to caspase-3 activated doxorubicin prodrug.

Cho YS, Chung SW, Kim HR, Won TH, Choi JU, Kim IS, Kim SY, Byun Y. Cho YS, et al. Among authors: chung sw. J Control Release. 2019 Feb 28;296:241-249. doi: 10.1016/j.jconrel.2019.01.020. Epub 2019 Jan 16. J Control Release. 2019. PMID: 30659905

2

Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor.

Lee E, Kim YS, Bae SM, Kim SK, Jin S, Chung SW, Lee M, Moon HT, Jeon OC, Park RW, Kim IS, Byun Y, Kim SY. Lee E, et al. Among authors: chung sw. Int J Cancer. 2009 Jun 15;124(12):2755-65. doi: 10.1002/ijc.24239. Int J Cancer. 2009. PMID: 19243020

3

Paclitaxel loaded nano-aggregates based on pH sensitive polyaspartamide amphiphilic graft copolymers.

Seo K, Chung SW, Byun Y, Kim D. Seo K, et al. Among authors: chung sw. Int J Pharm. 2012 Mar 15;424(1-2):26-32. doi: 10.1016/j.ijpharm.2011.12.047. Epub 2011 Dec 31. Int J Pharm. 2012. PMID: 22226879

4

Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex.

Kim JY, Shim G, Choi HW, Park J, Chung SW, Kim S, Kim K, Kwon IC, Kim CW, Kim SY, Yang VC, Oh YK, Byun Y. Kim JY, et al. Among authors: chung sw. Biomaterials. 2012 Jun;33(17):4424-30. doi: 10.1016/j.biomaterials.2012.02.066. Epub 2012 Mar 17. Biomaterials. 2012. PMID: 22425551

5

Strategies for non-invasive delivery of biologics.

Chung SW, Hil-lal TA, Byun Y. Chung SW, et al. J Drug Target. 2012 Jul;20(6):481-501. doi: 10.3109/1061186X.2012.693499. Epub 2012 May 28. J Drug Target. 2012. PMID: 22632037 Review.

6

Potentiation of anti-angiogenic activity of heparin by blocking the ATIII-interacting pentasaccharide unit and increasing net anionic charge.

Chung SW, Lee M, Bae SM, Park J, Jeon OC, Lee HS, Choe H, Kim HS, Lee BS, Park RW, Kim SY, Byun Y. Chung SW, et al. Biomaterials. 2012 Dec;33(35):9070-9. doi: 10.1016/j.biomaterials.2012.09.002. Epub 2012 Sep 23. Biomaterials. 2012. PMID: 23010574

7

Cyclic RGDyk-conjugated LMWH-taurocholate derivative as a targeting angiogenesis inhibitor.

Adulnirath A, Chung SW, Park J, Hwang SR, Kim JY, Yang VC, Kim SY, Moon HT, Byun Y. Adulnirath A, et al. Among authors: chung sw. J Control Release. 2012 Nov 28;164(1):8-16. doi: 10.1016/j.jconrel.2012.10.001. Epub 2012 Oct 10. J Control Release. 2012. PMID: 23063549

8

An apoptosis-homing peptide-conjugated low molecular weight heparin-taurocholate conjugate with antitumor properties.

Bae SM, Kim JH, Chung SW, Byun Y, Kim SY, Lee BH, Kim IS, Park RW. Bae SM, et al. Among authors: chung sw. Biomaterials. 2013 Mar;34(8):2077-86. doi: 10.1016/j.biomaterials.2012.11.020. Epub 2012 Dec 11. Biomaterials. 2013. PMID: 23245333

9

Oligomeric bile acid-mediated oral delivery of low molecular weight heparin.

Al-Hilal TA, Park J, Alam F, Chung SW, Park JW, Kim K, Kwon IC, Kim IS, Kim SY, Byun Y. Al-Hilal TA, et al. Among authors: chung sw. J Control Release. 2014 Feb 10;175:17-24. doi: 10.1016/j.jconrel.2013.12.001. Epub 2013 Dec 12. J Control Release. 2014. PMID: 24333628

10

Preliminary safety evaluation of a taurocholate-conjugated low-molecular-weight heparin derivative (LHT7): a potent angiogenesis inhibitor.

Alam F, Chung SW, Hwang SR, Kim JY, Park J, Moon HT, Byun Y. Alam F, et al. Among authors: chung sw. J Appl Toxicol. 2015 Jan;35(1):104-15. doi: 10.1002/jat.2995. Epub 2014 Feb 16. J Appl Toxicol. 2015. PMID: 24532548

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

715 results

Search Page

Filters